CLIFFORD GARVIN: Open Payments
NPI 1528095502 · DENISON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$501 in 26 payments from 12 companies in 2025. Trend: 2023 $653 · 2024 $874 · 2025 $501
Food & beverage: $501
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 8 | $150 |
| ABBVIE INC. | 4 | $74 |
| Corcept Therapeutics | 2 | $48 |
| GlaxoSmithKline, LLC. | 2 | $48 |
| Phathom Pharmaceuticals, Inc. | 2 | $31 |
| AstraZeneca Pharmaceuticals LP | 2 | $28 |
| Vanda Pharmaceuticals Inc. | 1 | $26 |
| Lilly USA, LLC | 1 | $24 |
| Viatris Specialty LLC | 1 | $20 |
| Paratek Pharmaceuticals, Inc. | 1 | $19 |
Products named: REXULTI, VRAYLAR, Korlym, TRELEGY ELLIPTA, VOQUEZNA, AIRSUPRA, FANAPT, KISUNLA.
Industry payments across TX — which companies pay providers there.
